About outlook therapeutics inc - OTLK
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
OTLK At a Glance
Outlook Therapeutics, Inc.
111 South Wood Avenue
Iselin, New Jersey 08830
| Phone | 1-609-619-3990 | Revenue | 1.41M | |
| Industry | Pharmaceuticals: Major | Net Income | -62,424,863.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 09 / 2026 | |||
| View SEC Filings |
OTLK Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 26.093 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.881 |
| Enterprise Value to Sales | 41.736 |
| Total Debt to Enterprise Value | 0.512 |
OTLK Efficiency
| Revenue/Employee | 83,149.118 |
| Income Per Employee | -3,672,050.765 |
| Receivables Turnover | 0.948 |
| Total Asset Turnover | 0.06 |
OTLK Liquidity
| Current Ratio | 0.38 |
| Quick Ratio | 0.307 |
| Cash Ratio | 0.176 |
OTLK Profitability
| Gross Margin | 46.494 |
| Operating Margin | -4,744.253 |
| Pretax Margin | -4,526.007 |
| Net Margin | -4,416.223 |
| Return on Assets | -263.355 |
| Return on Equity | N/A |
| Return on Total Capital | 3,132.264 |
| Return on Invested Capital | N/A |
OTLK Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -1,515.066 |
| Total Debt to Total Assets | 162.475 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -9.473 |